The Royalty Rate Report 2012: A Comprehensive Assessment of Valuation in the Pharmaceutical Sector
|
This Report, published March 2012, is the pharmaceutical and biotech industry’s standard reference work on royalty rates, published annually by PharmaDeals. |
The 2012 Report presents:
- Major new case studies
- Full, new data and analysis based on data from the premier agreements database, PharmaDeals® v4, and other sources
- Topics including Royalties and Deal Structures, Sales Milestones, Tiered Royalties, Alternative Structures, Technology Deals, Deal Creativity, Upfront Payments and Milestones, Royalties and IP Values and Market Cap, and Royalty Rates by Phase and Indication.
- Data and analysis of a recent major survey undertaken by PharmaDeals about royalties and changes in deal making over the last 5 years
- A glossary, and a wealth of figures and tables
The 2012 Report presents:
- Major new case studies
- Full, new data and analysis based on data from the premier agreements database, PharmaDeals® v4, and other sources
- Topics including Royalties and Deal Structures, Sales Milestones, Tiered Royalties, Alternative Structures, Technology Deals, Deal Creativity, Upfront Payments and Milestones, Royalties and IP Values and Market Cap, and Royalty Rates by Phase and Indication.
- Data and analysis of a recent major survey undertaken by PharmaDeals about royalties and changes in deal making over the last 5 years
- A glossary, and a wealth of figures and tables
The Report updates previous editions with a review of methods for calculating royalties, including topics such as research and development costs, benchmarking, transfer pricing, the basics of eNPV and NPV calculation, cash flows, relevant costs, risk and cash burn.
Contact us today
pdenquiries@uk.imshealth.com
pdenquiries@uk.imshealth.com
New for 2012:
The Royalty Rate Report 2012 will be published as a hardcopy report as well as an online interactive 'PharmaDeals iReport' access:
Client Information
If you are a subscriber of PharmaDeals v4 Agreements database, benefit from extensive linking options to and from the v4 database to the Royalty Rate Reports.
The Royalty Rate Report 2012 will be part of PharmaDeals v4 Enterprise Edition – the integrated resource with a comprehensive, interactive library of reports and data. Contact us now for a demonstration.
- Full searchability - fast and powerful search across the full text of all reports
- Presentation-ready tables and graphics - just select and drag the tables and graphics directly into your own documents
- Nine language translation - view any report with a 'side-by-side' translation in French, German, Italian, Portuguese, Spanish, Chinese, Japanese, Korean or Russian
- "Cut your own report" - use a keyword search to select only the report sections that are relevant to your project
Client Information
If you are a subscriber of PharmaDeals v4 Agreements database, benefit from extensive linking options to and from the v4 database to the Royalty Rate Reports.
The Royalty Rate Report 2012 will be part of PharmaDeals v4 Enterprise Edition – the integrated resource with a comprehensive, interactive library of reports and data. Contact us now for a demonstration.
Login Problems
